Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTIVEN)

Drug Name
Metronidazole Drug Info
Synonyms
APMN; Acromona; Anagiardil; Arilin; Atrivyl; Bexon; CONT; Clont; Danizol; Deflamon; Efloran; Elyzol; Entizol; Eumin; Flagemona; Flagesol; Flagil; Flagyl; Flegyl; Florazole; Fossyol; Giatricol; Gineflavir; Giniflavir; Klion; Klont; Meronidal; Methronidazole; Metric; MetroCream; MetroGel; MetroLotion; Metrodzhil; Metrogyl; Metrolag; Metrolyl; Metromidol; Metronidaz; Metronidazol; Metronidazolo; Metronidazolum; Metrotop; Metrozine; Metryl; Mexibol; Monagyl; Monasin; NIDA; Nalox; Nidagel; Noritate; Novonidazol; Orvagil; Protostat; Rathimed; Rosased; Sanatrichom; Satric; Takimetol; Trichazol; Trichex; Trichocide; Trichomol; Trichopal; Trichopol; Tricocet; Tricom; Trikacide; Trikamon; Trikojol; Trikozol; Trimeks; Trivazol; Vagilen; Vagimid; Vandazole; Vertisal; Wagitran; Zadstat; Zidoval; Flagyl Er; Ginefla vir; METRONIDAZOLE USP; Metro Cream; Metro Gel; Metronidazole Monohydrochloride; Metronidazole Phosphoester; Metronidazole in Plastic Container; Metronidazolo [DCIT]; Tricho cordes; Trichomonacid pharmachim; Tricowas B; Bayer 5360; Flagyl 375; M0924; Metric 21; RP 8823; SC 10295; Anabact (TN); Apo-Metronidazole; Deflamon-wirkstoff; Flagyl (TN); IDR-90105; METRO I.V; MetroGel (TN); MetroGel-Vaginal; Metronidazol [INN-Spanish]; Metronidazolum [INN-Latin]; Mexibol (silanes); Neo-Tric; Noritate (TN); RP-8823; Rozex (TN); Tricho-gynaedron; ZERO/004064; CB-01-14 MMX; FLAGYL I.V. RTU IN PLASTIC CONTAINER; Flagyl I.V.; Flagyl I.V. RTU; Metro I.V.; Metro I.V. In Plastic Container; Metrogel-vaginal (TN); Metronidazole (JP15/USP/INN); Metronidazole [USAN:INN:BAN:JAN]; Methyl-5-nitroimidazole-1-ethanol; 1-Hydroxyethyl-2-methyl-5-nitroimidazole; 2-(2-methyl-5-nitroimidazol-1-yl)ethanol; 2-Methyl-5-nitro-1-imidazoleethanol; 2-Methyl-5-nitroimidazole-1-ethanol; MNZ
Indication
Disease Entry ICD 11 Status REF
Abscess Approved [1]
Amoebiasis 1A36 Approved [2]
Anaerobic bacteria infectious disease Approved [1]
Bacteremia 1A73 Approved [1]
Bacterial vaginosis MF3A Approved [1]
Bladder squamous cell carcinoma Approved [1]
Endometritis Approved [1]
Liver abscess (disease) Approved [1]
Peritonitis Approved [1]
Trichomoniasis Approved [1]
Crohn disease DD70 Phase 3 [3]
Perianal crohn disease DD70.4 Phase 3 [4]
Giardiasis Investigative [1]
Therapeutic Class
Antiinfective Agents
Cross-matching ID
PubChem CID
4173
ChEBI ID
CHEBI:6909
CAS Number
CAS 443-48-1
TTD Drug ID
DMTIVEN
INTEDE Drug ID
DR1073
ACDINA Drug ID
D00425

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Bacterial Deoxyribonucleic acid (Bact DNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [18]
Clofazimine DMEBOFW Crohn disease DD70 Approved [19]
Hydroxystilbamidine Isethionate DMR5QS6 Blastomycosis 1F22 Approved [20]
Furazolidone DM3P6V7 Diarrhea ME05.1 Approved [21]
Proflavine DMF1X5P Sepsis 1G40-1G41 Approved [22]
MGB-BP-3 DMPBTVK Clostridium infection 1A04 Phase 2 [23]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [24]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [25]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [26]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [27]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [29]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [30]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [31]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [25]
Verapamil DMA7PEW Angina pectoris BA40 Approved [32]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By UDP-glucuronosyltransferase 1A1 (UGT1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [33]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [34]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [35]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [36]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [37]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [39]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [40]
Ethanol DMDRQZU Chronic pain MG30 Approved [41]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2A6 (CYP2A6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [43]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [7]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [44]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [28]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [7]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [45]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [46]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [7]
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [48]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [49]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [50]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [52]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [53]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [55]
Verapamil DMA7PEW Angina pectoris BA40 Approved [56]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A7 (CYP3A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [57]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [51]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [51]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [51]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [7]
Verapamil DMA7PEW Angina pectoris BA40 Approved [58]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [51]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [51]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [51]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [60]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [61]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [62]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [7]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [63]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [7]
Verapamil DMA7PEW Angina pectoris BA40 Approved [64]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [65]
Estrone DM5T6US Acne vulgaris ED80 Approved [66]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Nitroreductase (NTR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [68]
P-nitrobenzoic acid DMVJUOZ N. A. N. A. Investigative [68]
Tindamax DM3OWT4 Bacterial infection 1A00-1C4Z Approved [12]
Secnidazole DMJ18YL Amoebiasis 1A36 Approved [12]
AI3-23606 DMHMT49 N. A. N. A. Phase 1 [12]
BENZOQUINONE DMNBA0G Discovery agent N.A. Investigative [12]
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [10]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [10]
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [10]
Nitrofurazone DMSM2KE Skin burns ME65.0 Approved [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Proepiregulin (EREG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [69]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [17]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [70]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [17]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [17]
Methotrexate DM2TEOL Anterior urethra cancer Approved [71]
Quercetin DM3NC4M Obesity 5B81 Approved [72]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [74]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [16]
Clindamycin DM15HL8 Acne vulgaris ED80 Approved [16]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [16]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [75]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [76]
Cefepime DMHVWIK Bacterial infection 1A00-1C4Z Approved [16]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [77]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [78]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [79]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [80]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [81]
Carbamazepine DMZOLBI Epilepsy 8A60-8A68 Approved [16]
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [16]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [82]
Allopurinol DMLPAOB Gout FA25 Approved [83]
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [84]
Selenium DM25CGV N. A. N. A. Approved [85]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [16]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [86]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [87]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Interleukin-24 (IL24)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [88]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [17]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [89]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [17]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [17]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [90]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [91]
Penbutolol DM4ES8F Hypertension BA00-BA04 Approved [17]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [91]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial Deoxyribonucleic acid (Bact DNA) TTS1W4A NOUNIPROTAC Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [6]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [7]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [8]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [9]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [9]
Nitroreductase (NTR) DEUW4J0 A0A376H6M5_ENTGA Substrate [10]
Nitroreductase (NTR) DEP7ECA B1R7B9_CLOPF Substrate [11]
Nitroreductase (NTR) DEAN5EW NFSB_ENTCL Substrate [12]
Nitroreductase (NTR) DE3U2Y6 A0A377KR04_ENTCA Substrate [10]
Nitroreductase (NTR) DEQGIMN A4K8Z3_ENTHI Substrate [13]
Nitroreductase (NTR) DE8R7QY A0A482G3K9_GIAIN Substrate [13]
Nitroreductase (NTR) DE2VSMT A2DZ34_TRIVA Substrate [13]
Nitroreductase (NTR) DELAPDY A0A1C0X0J8_BACFG Substrate [14] , [15]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1) OTVVI3UI DQB1_HUMAN Gene/Protein Processing [16]
HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) OTRGGIFP DRB1_HUMAN Gene/Protein Processing [16]
Interleukin-24 (IL24) OT4VUWH1 IL24_HUMAN Gene/Protein Processing [17]
Proepiregulin (EREG) OTRM4NQY EREG_HUMAN Gene/Protein Processing [17]

References

1 Metronidazole FDA Label
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018517.
3 ClinicalTrials.gov (NCT00509639) Evaluation of Topical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn's Disease. U.S. National Institutes of Health.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 DNA breakage due to metronidazole treatment. Mutat Res. 2001 Jul 1;478(1-2):153-8.
6 Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? Ann Pharmacother. 2007 Apr;41(4):653-8.
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
9 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
10 Mechanism of metronidazole-resistance by isolates of nitroreductase-producing Enterococcus gallinarum and Enterococcus casseliflavus from the human intestinal tract. FEMS Microbiol Lett. 2003 Aug 29;225(2):195-200.
11 Acetamide--a metabolite of metronidazole formed by the intestinal flora. Biochem Pharmacol. 1979 Dec 15;28(24):3611-5.
12 Overexpression, isotopic labeling, and spectral characterization of Enterobacter cloacae nitroreductase. Protein Expr Purif. 1998 Jun;13(1):53-60.
13 Giardia, Entamoeba, and Trichomonas enzymes activate metronidazole (nitroreductases) and inactivate metronidazole (nitroimidazole reductases). Antimicrob Agents Chemother. 2009 Feb;53(2):458-64.
14 Isolation of metronidazole-resistant Bacteroides fragilis carrying the nimA nitroreductase gene from a patient in Washington State. J Clin Microbiol. 2004 Sep;42(9):4127-9. Case Reports
15 Biotransformation of 1-nitropyrene in intestinal anaerobic bacteria. Microbiol Immunol. 1982;26(11):993-1005.
16 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
17 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
18 On the nature of the adaptive response induced by mitomycin C in Vibrio cholerae OGAWA 154 cells. Biochem Biophys Res Commun. 1996 Mar 27;220(3):509-14.
19 The mode of action of clofazimine DNA binding studies. Int J Lepr Other Mycobact Dis. 1976 Jan-Jun;44(1-2):133-4.
20 Interaction between hydroxystilbamidine and DNA. I. Binding isotherms and thermodynamics of the association. Biochim Biophys Acta. 1975 Sep 12;407(1):24-42.
21 Interaction of furazolidone with DNA. Biochim Biophys Acta. 1975 Aug 21;402(2):161-5.
22 Interaction of small molecules with double-stranded RNA: spectroscopic, viscometric, and calorimetric study of hoechst and proflavine binding to PolyCG structures. DNA Cell Biol. 2009 Apr;28(4):209-19.
23 Clinical pipeline report, company report or official report of MGB Biopharma.
24 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
25 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
26 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
27 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
28 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
29 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
30 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
31 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
32 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
33 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
34 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
35 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
36 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
37 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
38 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
39 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
40 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
41 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
42 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
43 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
44 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
45 Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
46 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
47 CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
48 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
49 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
50 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
51 Drug Interactions Flockhart Table
52 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
53 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
54 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
55 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
56 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
57 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
58 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
59 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
60 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
61 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
62 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
63 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
64 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
65 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
66 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
67 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
68 Isolation of nitrofurantoin-resistant mutants of nitroreductase-producing Clostridium sp. strains from the human intestinal tract. Antimicrob Agents Chemother. 1998 May;42(5):1121-6.
69 Cannabidiol-induced transcriptomic changes and cellular senescence in human Sertoli cells. Toxicol Sci. 2023 Feb 17;191(2):227-238. doi: 10.1093/toxsci/kfac131.
70 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
71 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
72 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
73 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
74 Retinoid-induced epidermal hyperplasia is mediated by epidermal growth factor receptor activation via specific induction of its ligands heparin-binding EGF and amphiregulin in human skin in vivo. J Invest Dermatol. 2006 Apr;126(4):732-9. doi: 10.1038/sj.jid.5700202.
75 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
76 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
77 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
78 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
79 Sulfur mustard alkylates steroid hormones and impacts hormone function in vitro. Arch Toxicol. 2019 Nov;93(11):3141-3152. doi: 10.1007/s00204-019-02571-x. Epub 2019 Sep 12.
80 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
81 The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria. Clin Exp Allergy. 2005 Mar;35(3):339-44. doi: 10.1111/j.1365-2222.2004.02197.x.
82 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
83 A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunogenet. 2011 Aug;38(4):303-9. doi: 10.1111/j.1744-313X.2011.01011.x. Epub 2011 May 4.
84 Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6.
85 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
86 Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers. Clin Breast Cancer. 2013 Oct;13(5):401-8.
87 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
88 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
89 ERE-independent ERalpha target genes differentially expressed in human breast tumors. Mol Cell Endocrinol. 2005 Dec 21;245(1-2):53-9. doi: 10.1016/j.mce.2005.10.003. Epub 2005 Nov 17.
90 Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther. 2005 Feb;4(2):291-304.
91 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.